Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,770 result(s) found for: cancer. Displaying page 65 of 139.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    EudraCT Number: 2016-004484-39 Sponsor Protocol Number: BAY1895344/18594 Start Date*: 2017-07-18
    Sponsor Name:Bayer AG
    Full Title: An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the A...
    Medical condition: Part A+A.1: Histologically confirmed solid tumors or NHL Part A J-arm : Advanced solid tumors Part B: a) DDR deficient advanced solid tumors: i) CRPC; ii) HER2- negative BC (estrogen-receptor posit...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000995-14 Sponsor Protocol Number: MIV-818-101/201 Start Date*: 2018-08-10
    Sponsor Name:Medivir AB
    Full Title: A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of...
    Medical condition: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or, metastatic liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027479 Metastatic liver carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001967-26 Sponsor Protocol Number: ACT16444 Start Date*: 2021-09-16
    Sponsor Name:Sanofi aventis recherche & développement
    Full Title: Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-000589-39 Sponsor Protocol Number: ADP-0044-002 Start Date*: 2020-02-13
    Sponsor Name:Adaptimmune LLC
    Full Title: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
    Medical condition: Advanced Synovial Sarcoma Myxoid/Round Cell Liposarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004568-72 Sponsor Protocol Number: ASTX029-01 Start Date*: 2021-05-27
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10053571 Melanoma LLT
    21.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003190-42 Sponsor Protocol Number: ANZUP1304 Start Date*: 2014-10-17
    Sponsor Name:Cancer Trials Ireland
    Full Title: Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMET
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001790-41 Sponsor Protocol Number: AB11002 Start Date*: 2013-04-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointesti...
    Medical condition: Gastrointestinal stromal tumor resistant to imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing) DE (Prohibited by CA) BE (Prematurely Ended) AT (Ongoing) GB (GB - no longer in EU/EEA) GR (Prematurely Ended) IT (Suspended by CA) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002893-11 Sponsor Protocol Number: PASIPHAE Start Date*: 2017-08-14
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced...
    Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004424-38 Sponsor Protocol Number: 011604QM Start Date*: 2017-11-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.
    Medical condition: Untreated, operable ER+, HER2-negative primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003959-16 Sponsor Protocol Number: CAAA405A12301 Start Date*: 2021-04-27
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase III study for evaluation of the diagnostic performance of [18F]CTT1057 PET imaging in patients with prostate cancer with rising PSA levels [biochemical recurrence (BCR)] (GuidePath)
    Medical condition: Prostate cancer with rising PSA levels [biochemical recurrence (BCR)]
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-002729-27 Sponsor Protocol Number: MK-3475-A86 Start Date*: 2021-09-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherap...
    Medical condition: Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002821-39 Sponsor Protocol Number: MCLA-128-CL02 Start Date*: 2017-11-13
    Sponsor Name:Merus N.V.
    Full Title: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive a...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) PT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004203-41 Sponsor Protocol Number: 54767414MMY2040 Start Date*: 2018-04-26
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000363-91 Sponsor Protocol Number: CX-839-008 Start Date*: 2018-08-10
    Sponsor Name:Calithera Biosciences Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced ...
    Medical condition: Advanced or metastatic clear-cell renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002234-14 Sponsor Protocol Number: OR2805-101 Start Date*: 2023-06-07
    Sponsor Name:OncoResponse, Inc.
    Full Title: A Phase 1-2 Study of OR2805 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
    Medical condition: Solid tumor cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004299-41 Sponsor Protocol Number: ERMES Start Date*: 2014-12-24
    Sponsor Name:Dipartimento di Scienze Mediche Oncologia Medica Policlinico Gemelli
    Full Title: ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by...
    Medical condition: Patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001789-39 Sponsor Protocol Number: LAVA1207-001 Start Date*: 2021-07-13
    Sponsor Name:LAVA Therapeutics N.V.
    Full Title: A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cel...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001300-35 Sponsor Protocol Number: UCL11/0034 Start Date*: 2012-01-31
    Sponsor Name:University College London
    Full Title: A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer
    Medical condition: Locally advanced cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008233 Cervical cancer stage I LLT
    21.1 100000004864 10008234 Cervical cancer stage II LLT
    21.1 100000004864 10008235 Cervical cancer stage III LLT
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000339-28 Sponsor Protocol Number: CA025-006 Start Date*: 2018-10-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer
    Medical condition: Advanced Pancreatic Cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001485-29 Sponsor Protocol Number: G1T38-02 Start Date*: 2017-03-21
    Sponsor Name:G1 Therapeutics, Inc
    Full Title: Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Bre...
    Medical condition: Hormone Receptor-Positive, HER2 Negative Metastatic Breast Cancer after Endocrine Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 61  62  63  64  65  66  67  68  69  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 15:51:54 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA